Z.A.R.S. und GERMAP
Erfassung, Auswertung und Präsentation von Daten über die Ausbreitung von Antibiotika-Resistenzen bei bakteriellen Infektionserregern in der Humanmedizin in Deutschland
Arzneimittelwesen
Abstract
Z.A.R.S. and GERMAP / Collection, analysis and presentation of data on the prevalence of antimicrobial resistance in human medicine in Germany
Antimicrobial resistance has emerged over the last 15 to 20 years in Germany and worldwide. The German Federal Government along with numerous other organizations has developed an action plan named “Deutsche Antibiotika-Resistenzstrategie (DART)” to combat this problem. From the point of view of human medicine, there are two major activities associated with DART, namely the reports issued by the working group GERMAP and the project of the corporate centre for the evaluation of resistance data on antibacterial agents applied systemically called Z.A.R.S.
The working group GERMAP regularly provides information on antibiotic consumption and antimicrobial resistance in human and veterinary medicine in order to identify the current and potential risks linked to the spread of resistant microorganisms in Germany and, by doing so, help that bacterial infections can still be treated successfully in the future.
Pursuing the same objective the Z.A.R.S. project has been established to assess the current resistance situation on more than 50 antibacterial agents indicated for systemic use and to generate herefrom the so called resistance tables for use in the Summaries of Product Characteristics (SPCs) of antibacterial medicinal products. The tables provide the attending physician with optimized information on the spread of resistance in those organisms that play a significant role as pathogens in the particular approved indications of the drug.
Zusammenfassung
Die Häufigkeit von bakteriellen Infektionserregern mit Resistenz gegenüber antibiotisch
